MeiraGTx Holdings PLC represents a set of core values and a corporate philosophy aimed at advancing gene therapies for rare diseases and providing innovative solutions. With a focus on building a diversified portfolio, MeiraGTx is committed to scientific excellence, patient advocacy, and collaborative partnerships. The company's vision revolves around bringing transformative treatments to patients in need while maintaining a patient-centric approach. MeiraGTx strives to integrate cutting-edge technologies and research to develop effective gene therapies, leveraging its expertise in gene regulation and optimization. By prioritizing integrity, innovation, and quality, MeiraGTx is dedicated to making a meaningful impact on patients' lives and advancing the field of gene therapy.

MeiraGTx Holdings PLC primarily operates in the United States and the United Kingdom.

MeiraGTx Holdings PLC has achieved various significant milestones. The company successfully completed a Phase 1/2 clinical trial for its experimental gene therapy product, AAV-RPGR, which aims to treat inherited retinal diseases. MeiraGTx also received fast track designation from the U.S. FDA for its AAV-RPGR program and secured Orphan Drug Designation for its investigational gene therapy product, AAV-CNGA3, for treating achromatopsia. Furthermore, the company entered into partnership agreements with Janssen Pharmaceuticals and additional collaboration agreements with Johnson & Johnson Innovation and Novartis Institutes for Biomedical Research. MeiraGTx's notable achievements reflect its commitment to advancing innovative therapies in the field of gene therapy.

MeiraGTx Holdings PLC is a leading clinical-stage gene therapy company. Founded in 2015, the company focuses on developing transformative treatments for various genetic diseases. Headquartered in New York City, MeiraGTx combines expertise in gene therapy, vector design, and manufacturing to advance novel therapies. The company's mission is to deliver life-changing benefits through innovative genetic medicines. With a strong portfolio of product candidates, MeiraGTx aims to address unmet needs in the areas of ophthalmology, salivary gland disorders, neurodegenerative diseases, and more. Through strategic partnerships and collaborations, MeiraGTx continues to make significant advancements in the field of gene therapy.

The main competitors of MeiraGTx Holdings PLC in the market include companies such as CRISPR Therapeutics AG, Editas Medicine Inc., and Intellia Therapeutics Inc.

MeiraGTx Holdings PLC is primarily active in the biotechnology and pharmaceutical industries.

The business model of MeiraGTx Holdings PLC is focused on the development and commercialization of gene therapies. As a biotechnology company, MeiraGTx aims to provide novel treatments for various genetic diseases by utilizing advanced gene therapy techniques. With a strong emphasis on innovation and research, MeiraGTx works towards addressing unmet medical needs in areas such as ophthalmology, neurology, and rare diseases. By leveraging its expertise in gene therapy, the company strives to bring transformative therapies to patients, improving their quality of life and offering potential new treatment options. MeiraGTx Holdings PLC is dedicated to advancing the field of gene therapy through its innovative business model.

MeiraGTx Holdings KGV ir -1,75.

MeiraGTx Holdings KUV ir 7,20.

AlleAktien kvalitātes vērtējums MeiraGTx Holdings ir 3/10.

gaidāmā MeiraGTx Holdings apgrozījums ir 32,78 milj. USD.

gaidāmā MeiraGTx Holdings peļņa ir -134,93 milj. USD.

MeiraGTx Holdings PLC is a leading company in the development of gene and cell therapies for patients with rare genetic diseases as well as for patients with hereditary retinal diseases that can lead to blindness. The company is divided into different divisions to focus on the two areas of gene and cell therapy. In the gene therapy division, MeiraGTx offers a range of products for a variety of diseases. For example, the company offers gene therapy for hemophilia B, where a defective gene is replaced that is necessary for blood clotting. In the cell therapy division, MeiraGTx is focused on developing therapies for hereditary retinal diseases. The company has global exclusive rights to market a product called AAV-RPGR. This product is an adeno-associated virus (AAV) that delivers a healthy copy of the RPGR gene into retinal cells. This therapeutic method is used to treat X-linked retinitis pigmentosa (XLRP), a rare disease that can lead to blindness. MeiraGTx utilizes a combination of proprietary and licensed technology. The company has an extensive library of adeno-associated viruses (AAV) that offer high efficiency and safety. MeiraGTx also collaborates closely with academics and researchers to accelerate progress in gene and cell therapy. MeiraGTx's business model is based on a proven approach to developing therapies for rare genetic diseases and hereditary retinal diseases. However, the development of these therapies is costly and involves lengthy clinical trials. To overcome this financial challenge, MeiraGTx has attracted investors who have a keen interest in this emerging field of medicine. Another component of MeiraGTx's business model is partnering with biopharmaceutical industry partners. For example, the company has formed a strategic partnership with Janssen Pharmaceutica NV, a Johnson & Johnson company. Under this agreement, MeiraGTx is working on the development of gene therapies for certain central nervous system disorders. Successful partnerships and collaboration with established pharmaceutical companies can help reduce the risk and cost of developing new therapies. Overall, MeiraGTx is a company built on a solid scientific foundation and focused on developing innovative medicines for rare genetic diseases and hereditary retinal diseases. The company's business model relies on a combination of proprietary and licensed technology, investor funding, and strategic partnerships. MeiraGTx has the potential to improve the lives of millions of people worldwide.

MeiraGTx Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt MeiraGTx Holdings vai uzņēmums nedod dividendes.

MeiraGTx Holdings ISIN ir KYG596651029.

MeiraGTx Holdings WKN ir A2JGHF.

MeiraGTx Holdings simbols ir MGTX.

Pēdējo 12 mēnešu laikā MeiraGTx Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos MeiraGTx Holdings plāno maksāt dividendes 0 USD apmērā.

MeiraGTx Holdings pašreizējā dividendu rentabilitāte ir .

MeiraGTx Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

MeiraGTx Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

MeiraGTx Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu MeiraGTx Holdings apmērā 0 USD, kas tika izmaksāta 21.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 21.09.2024..

Pēdējās dividendes izmaksa notika 21.09.2024..

Gadā 2023, MeiraGTx Holdings izmaksāja 0 USD dividendes.

MeiraGTx Holdings dividendes tiek izmaksātas USD.